CM
AKRO

Caption Management’s Akero Therapeutics AKRO Stock Holding History

Caption Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-39,500
Closed -$1.88M – 1538
2025
Q3 		$1.88M Buy
39,500
+8,162
+26% +$395K 0.01% 868
2025
Q2 		$1.67M Buy
31,338
+26,738
+581% +$1.21M 0.02% 778
2025
Q1 		$186K Buy
+4,600
New +$195K ﹤0.01% 1287
2024
Q4 		– Sell
-10,087
Closed -$289K – 1434
2024
Q3 		$289K Buy
+10,087
New +$263K ﹤0.01% 1017
2024
Q2 		– Sell
-10,269
Closed -$259K – 1123
2024
Q1 		$259K Buy
10,269
+9,738
+1,834% +$234K ﹤0.01% 971
2023
Q4 		$12.4K Sell
531
-734
-58% -$14.5K ﹤0.01% 1265
2023
Q3 		$64K Sell
1,265
-10,835
-90% -$504K ﹤0.01% 1184
2023
Q2 		$565K Sell
12,100
-10,060
-45% -$461K 0.01% 794
2023
Q1 		$848K Buy
22,160
+17,060
+335% +$761K 0.02% 672
2022
Q4 		$279K Buy
+5,100
New +$219K ﹤0.01% 1016
2020
Q2 		– Sell
-900
Closed -$19K – 909
2020
Q1 		$19K Buy
+900
New +$19.3K ﹤0.01% 810

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Caption Management's AKRO Position: Q4 2025 in Review

Caption Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 39,500 shares — an estimated $1.88M sold.

Caption Management first reported a position in AKRO in Q1 2020 and held it in 11 quarters. The position peaked at $1.88M in Q3 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Caption Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Caption Management sold 39,500 Akero Therapeutics shares in Q4 2025, an estimated $1.88M.
  • Caption Management first reported a position in Akero Therapeutics in Q1 2020 and held it in 11 quarters.
  • Caption Management's Akero Therapeutics position peaked at $1.88M in Q3 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Caption Management's 13F filing for Q4 2025, filed 17 Feb 2026.